Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Dallas—Physicians may soon have another option available for reducing stroke risk in patients with atrial fibrillation.
At the Scientific Sessions of the American Heart Association (AHA) held here in November, attendees heard promising results regarding edoxaban, an oral factor Xa inhibitor that was found to be noninferior to well-managed warfarin (median time in the therapeutic range, 68.4%) for the prevention of stroke or systemic embolism. Edoxaban use was also associated with lower rates of bleeding and death from cardiovascular causes when compared with warfarin, the vitamin K antagonist and most widely prescribed anticoagulant medicine (Giugliano RP et al. N Eng J Med. doi:10.1056/NEJMoa1310907 [published online November 19, 2013]).
Mitka M. Another Novel Oral Anticoagulant Matches Warfarin. JAMA. 2014;311(3):233-234. doi:10.1001/jama.2013.284833